21320-30-9

Usage

Uses

Used in Adhesives Industry:
2-[(3,4-DICHLOROPHENOXY)METHYL]OXIRANE is used as a key component in the production of epoxy resins for its ability to create strong, durable adhesives that bond various materials effectively.
Used in Coatings Industry:
In the coatings industry, 2-[(3,4-DICHLOROPHENOXY)METHYL]OXIRANE is utilized as a vital ingredient in epoxy resins, which provide coatings with enhanced durability, chemical resistance, and adhesion properties.
Used in Plastics Industry:
2-[(3,4-DICHLOROPHENOXY)METHYL]OXIRANE is employed in the plastics industry as it is a fundamental constituent of epoxy resins. These resins contribute to the manufacturing of high-performance plastics with improved mechanical and thermal properties.
Used in Pharmaceutical Industry:
Within the pharmaceutical sector, 2-[(3,4-DICHLOROPHENOXY)METHYL]OXIRANE is used as an intermediate in the synthesis of various drugs, highlighting its importance in drug development and production.
Used as a Solvent:
2-[(3,4-DICHLOROPHENOXY)METHYL]OXIRANE is used as a solvent for resins and waxes, capitalizing on its ability to dissolve a wide range of substances, thus facilitating various manufacturing processes.
Given the hazardous nature of 2-[(3,4-DICHLOROPHENOXY)METHYL]OXIRANE, it is imperative that its applications are conducted with strict adherence to safety protocols to minimize health and environmental risks.

InChI:InChI=1/C9H8Cl2O2/c10-8-2-1-6(3-9(8)11)12-4-7-5-13-7/h1-3,7H,4-5H2

Upstream product

• 39975-26-3 sodium 3,4-dichlorophenoxide 
• 106-89-8 epichlorohydrin 
• 95-77-2 3,4-dichlorophenol 

Downstream Products

• 132948-72-2 1-(3,4-Dichloro-phenoxy)-3-piperidin-1-yl-propan-2-ol 
• 1311146-80-1 1-(((1-(2-chlorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl)methyl)(methyl)amino)-3-(3,4-dichlorophenoxy)propan-2-ol 
• 59692-59-0 1-(3,4-dichlorophenoxy)-3-tert-butylamino-2-propanol 
• 5790-30-7 3-<3.4-Dichlor-phenoxy>-1-isopropylamino-propanol-(2) 

Relevant academic research and scientific papers

Substituted diaryl compound and preparation method and application thereof

The invention relates to the field of medicinal chemistry, in particular to a substituted diaryl compound (I). The preparation method comprises the following steps: medicine preparation and medical application thereof. Test results show that the substituted diaryl compound has a good inhibition effect on human lung cancer (A549), human ovarian cancer (SKOV3), human melanoma (A375) and human colon cancer (LOVO) cells. Formula (I):

THERAPEUTIC COMPOUNDS

The present invention relates to therapeutic compounds useful for the treatment of neurodegenerative and neuromuscular diseases and/or triplet repeat diseases (e.g. Friedreich's ataxia). The compounds have the structural formula I shown below: wherein Q, X, p, R1, q, R3 and R4 are as defined herein. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein, the use of these compositions for the treatment of neurodegenerative and neuromuscular diseases and/or triplet repeat diseases (e.g. Friedreich's ataxia), and to processes for the preparation of the pharmaceutical compositions defined herein.

Development of β-amino alcohol derivatives that inhibit toll-like receptor 4 mediated inflammatory response as potential antiseptics

Toll-like receptor 4 (TLR4) induced proinflammatory signaling has been directly implicated in severe sepsis and represents an attractive therapeutic target. Herein, we report our investigations into the structure-activity relationship and preliminary drug metabolism/pharmacokinetics study of β-amino alcohol derivatives that inhibit the TLR4 signaling pathway. Lead compounds were identified from in vitro cellular examination with micromolar potency for their inhibitory effects on TLR4 signaling and subsequently assessed for their ability to suppress the TLR4-induced inflammatory response in an ex vivo whole blood model. In addition, the toxicology, specificity, solubility, brain-blood barrier permeability, and drug metabolism of several compounds were evaluated. Although further optimizations are needed, our findings lay the groundwork for the future drug development of this class of small molecule agents for the treatment of severe sepsis.

SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF

The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.